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Purpose. Transdermal iontophoresis was investigated as a noninva-
sive tool for drug monitoring and pharmacokinetic profiling. Lithium,
a frequently monitored drug, was used as a model. The objectives
were a) to demonstrate the linear dependence of the iontophoretic
extraction flux of lithium on the subdermal concentration of the drug,
b) to evaluate the capacity of iontophoresis to monitor sudden
changes in the subdermal level, c) to investigate the utility of reverse
iontophoresis as a tool in pharmacokinetic studies, and d) to examine
the validity of an internal standard calibration procedure to render
the method completely noninvasive.
Methods. Transdermal, iontophoretic extraction was performed in vitro
using dermatomed pig-ear skin. The subdermal solution consisted of
a physiological buffer containing lithium chloride at concentrations in
the therapeutic range and two putative internal standards, sodium
and potassium, at fixed physiological levels. The subdermal concen-
tration of lithium was changed either in a stepwise fashion or by
simulating one of two pharmacokinetic profiles.
Results. Lithium was extracted via electromigration to the cathode.
A excellent correlation between subdermal lithium concentration and
iontophoretic extraction flux was observed. Iontophoresis tracked
sudden concentration changes and followed kinetic profiles. In addi-
tion, the effective elimination rate constant could be directly, and
noninvasively, estimated from the extraction flux data.
Conclusions. Reverse iontophoresis is a potentially useful and non-
invasive tool for lithium monitoring.
KEY WORDS: iontophoresis; lithium; reverse iontophoresis; thera-
peutic drug monitoring; transdermal extraction.
INTRODUCTION
Currently, therapeutic drug monitoring and pharmacoki-
netic studies depend principally upon the quantification of the
molecule in one or more blood samples. The invasive nature
of the procedure, the associated risks of infection, the need
for trained personnel, and, for some populations (e.g., neo-
nates), the technical difficulty, limit the frequency and com-
plexity of these studies. As a result, drug kinetics in certain
patient groups are poorly understood, and drug monitoring,
in general, is performed much less often than it should.
There is a clear need, therefore, for the development of
noninvasive techniques, which would be much better ac-
cepted by the patient and would offer the possibility of fre-
quent and ambulatory self-monitoring (1,2). Pediatric, neona-
tal, and geriatric patients, as well as the chronically and criti-
cally ill, would benefit most from the availability of such tools.
For example, manic-depressive patients receiving chronic
lithium therapy would profit from frequent monitoring that
does not demand repeated visits to the hospital. These pa-
tients are carefully supervised because of a) the wide inter-
subject variability observed in dose requirement and toler-
ance to the drug, b) the very narrow therapeutic index, and c)
a half-life that depends on kidney function, sodium intake,
and age (3). Monitoring is initially performed to adjust the
dose: daily, weekly and, finally, monthly evaluations are car-
ried out during the first 6 months. Thereafter, lithium levels
are checked at least every three months to detect drifts in
concentration (4). The latter may be due to age, pregnancy,
low salt diet, fever, infection, drug interactions, other medical
problems, and/or poor compliance with the dosage regimen
(4–6). At present, lithium monitoring requires blood sam-
pling. Attempts to use either saliva or urine as alternative
matrices have not been successful (3,7–9).
Reverse, transdermal iontophoresis has been proposed
as an alternative technique for noninvasive monitoring (10–
15). Potential applications in clinical chemistry and thera-
peutic drug monitoring have been identified. Iontophoresis
involves the application of a small electrical current (<0.5
mA/cm2) to the skin (16,17) and results in enhanced transport
across the membrane via two possible mechanisms (18–20).
The first, electromigration, only concerns ions, which carry
the current through the skin toward the electrode of opposite
polarity. Thus, in reverse iontophoresis, anions are extracted
at the anode and cations (such as lithium) at the cathode
(negative electrode). The ion flux is related to the intensity of
current applied via equation 1:
Ja =
I  ta
za  F
(1)
where, Ja, ta, and za are the flux, transport number, and va-
lence, respectively, of the ion “a”; I is the intensity of current
applied, and F is Faraday’s constant. It has been shown that,
in the presence of competing ions, the transport number (i.e.,
the percentage of the charge carried) of a given ion is pro-
portionally related to its concentration in the donor solution
(21). Thus, in reverse iontophoresis, it is expected that the
flux of a given analyte should be related to its concentration
in the subdermal fluid. The second mechanism of transport is
electroosmosis, which is a convective solvent flow, in the an-
ode-to-cathode direction, due to the fact that the skin has a
net negative charge. This flow increases the transdermal
transport of neutral (e.g., glucose) and zwitterionic species
and supplements the electromigration of cations. It has also
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ABBREVIATIONS: J, extraction flux (units: nmol/h); RI.S., ratio
between lithium (Li) and internal standard (I.S.) extraction fluxes
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been shown that the electroosmotic transport of an analyte is
directly proportional to the concentration of the species pres-
ent in the solvent (19,22).
The Glucowatch Biographer (Cygnus, Inc., Redwood
City, CA, USA), which monitors blood sugar, is the only
approved reverse iontophoretic system on the market (23).
Before use, the device has to be calibrated via a conventional
finger-stick so that the amount of electroosmotically ex-
tracted glucose (measured in situ by the appparatus), in a
defined period of current passage, can be related to the cor-
responding blood level. At present, it is unknown whether
iontophoretic devices relying on electromigrative extraction
will also require a similar calibration; such would be the case,
for example, if the transport number of a specific ion dem-
onstrated a significant inter-individual variability in vivo.
In any case, the development of a noninvasive calibration
procedure can clearly be identified as a sensible priority for
future applications of reverse iontophoresis in drug monitor-
ing, and, recently, the use of an “internal standard” approach
has been proposed (10,11,24). The procedure takes advantage
of the fact that iontophoretic extraction is not specific. For
example, in the case of lithium, several other cations will be
simultaneously extracted at the cathode. If one of these ions,
which may be referred to as the “internal standard,” is present
in the body at a relatively constant concentration, then its
iontophoretic flux (JI.S.) would be expected to be constant as
well. It follows that the ratio of the extraction fluxes, JLi/JI.S,
should be directly proportional to the ratio of their respective
concentrations (CLi/CI.S.) (10,11,24). Given that CI.S. is con-
stant, JLi/JI.S. becomes directly proportional to CLi:
JLiJI.S. = RI.S. = 
#  CLi (2)
where # is a constant. This hypothesis is tested here using
sodium and potassium as candidate internal standards for
lithium.
In summary, this work explores the potential of reverse
iontophoresis as a noninvasive procedure for lithium moni-
toring and for pharmacokinetic profiling. In particular, the
following questions have been addressed: i) Are iontophoret-
ic extraction fluxes of lithium proportional to the correspond-
ing subdermal concentrations? ii) Is iontophoresis capable of
following sudden changes in the lithium subdermal concen-
tration? iii) To what extent may reverse iontophoresis be use-
ful for pharmacokinetic studies? iv) Does the “internal stan-
dard” calibration approach work?
MATERIALS AND METHODS
Materials
Eight molar (8 M) LiCl solution, NaCl, KCl, NaOH,
KOH, Hepes, Tris, TrisHCl, Mops, Ag wire 99.9%, AgCl
99%, and Pt 99.9% were purchased from Sigma-Aldrich
(Saint Quentin Fallavier, France). Deionized water (resistiv-
ity 18.2 M  cm) was used to prepare all solutions.
Skin Preparation
Porcine ears were obtained fresh from the local slaugh-
terhouse (S.O.D.E.X.A., Annecy, France) and were cleaned
under cold running water. The whole skin was removed care-
fully from the outer region of the ear and separated from the
underlying cartilage with a scalpel. Both full thickness and
dermatomed (∼750 m) skin were used. The skin was
wrapped individually in Parafilm and maintained at –20°C for
no longer than 2 months. All experiments were performed
with 3 to 6 replicates, using skin samples originating from
different pigs.
Equipment
Two types of iontophoretic cells were used: a) vertical
iontophoretic cells (25) with an effective transport area of
0.78 cm2, a 6.5-ml subdermal volume and 1-ml electrode
chambers; and b) side-by-side three-compartment cells (11)
with a 1-cm2 skin surface area, a 4.54 ± 0.15 ml subdermal
compartment, and 1.5-ml electrode chambers. Access ports to
the subdermal compartment permitted the lithium concentra-
tion to be perfused at a fixed level, to be changed abruptly,
and to be modulated continuously over time so as to mimic
a pharmacokinetic profile. A manual power supply (either a
KEPCO 1000M, Flushing, NY, USA, or a Yokogawa 7651,
Tokyo, Japan) was used to deliver a constant current via
Ag/AgCl electrodes (26).
Fixed-Concentration Extraction Experiments
Full-thickness skin was clamped in vertical iontophoretic
cells. First, the subdermal and anodal compartments were
filled with a pH 7.4 buffer comprising 25 mM Hepes and
133 mM NaCl. The cathodal compartment was filled with a
pH 7.4 buffer comprising 25 mM Hepes and 10 mM KCl.
After 30 min equilibration, the anodal and cathodal so-
lutions were refreshed. The subdermal chamber was filled
with the “donor” solution, which consisted of the same buffer
to which lithium chloride was added at one of three different
concentrations (0.6, 1.0, and 1.5 mM) corresponding to the
drug’s therapeutic range. Iontophoresis was performed for 5 h
by applying a constant current of 0.4 mA via Ag/AgCl elec-
trodes. The current was stopped hourly to permit the collec-
tion and replacement of the entire electrode chambers solu-
tions. Three replicates were made. The samples were assayed
for lithium by graphite furnace atomic spectrometry (GFAS).
Stepwise Concentration Change Experiments
Dermatomed skin was clamped between the three com-
partments of side-by-side cells. During a 30-min equilibration
period, the subdermal compartment was filled with 3.5 ml of
a pH 7.4 buffer solution containing 32 mM Tris, 34 mM Mops
and 133 mM NaCl. The anodal chamber was filled with a pH
7.4 buffer comprising 90 mM Tris/Tris HCl, whereas the
cathodal chamber was also buffered at physiological pH with
32 mM Tris and 34 mM Mops. Subsequently, the anodal and
cathodal solutions were refreshed. The subdermal chamber
was filled with the same buffer to which 4 mM potassium
chloride and lithium chloride at either 0.95 mM (first experi-
ment) or 1.7 mM (second experiment) were added. The con-
centration of LiCl in the subdermal donor solution was then
changed in a stepwise fashion at 120 and 210 min: in the first
experiment, to 2.7 mM and 1.8 mM, respectively; in the sec-
ond, to 0.6 and 1.1 mM.
Iontophoresis was performed for 5 h at a constant cur-
rent of 0.4 mA. Six replicates were carried out. Every 30 min,
the current was stopped and the entire electrode chamber
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solutions were sampled and refilled with fresh buffer. The
samples were assayed for lithium by graphite furnace atomic
spectrometry (GFAS) and for potassium and sodium by flame
atomic absorption spectrometry (FAAS).
Concentration-Profile Kinetic Experiments
Dermatomed skin was clamped in side-by-side cells. Af-
ter an equilibration period as described before, the solutions
in the three compartments were refreshed. Then, the lithium
content of the subdermal solution was varied to simulate the
plasma concentration profile observed after either an IV
bolus or a continuous infusion (see below). Iontophoresis was
performed at a constant current of 0.4 mA for 5 h. Every
30 min, the current was stopped (for a period of ∼5 min) to
permit the collection and the replacement of the entire elec-
trode solutions. At the midpoint of each of iontophoretic pe-
riod, 10 l of the subdermal solution were sampled, and the
actual concentrations of lithium, sodium and potassium
therein were quantified by ionic chromatography with con-
ductimetric detection, allowing their iontophoretic extraction
fluxes to be calculated.
Intravenous Bolus
A syringe pump (Genie 8, Kent Scientific Corporation,
Torrington CT, USA) infused the subdermal buffer (pH 7.4,
32 mM Tris, 34 mM Mops, 133 mM NaCl, 4 mM KCl) at a rate
of 1 ml/h. After 1 h of iontophoresis, 6.2 l of a 0.8 M aqueous
solution of LiCl were directly added via a bolus injection into
the subdermal compartment of each cell.
Constant Rate Infusion
A syringe pump infused the subdermal buffer as before,
but at a rate of 4 ml/h. After 1 h of iontophoresis, the com-
position of the infused solution was modified to incorporate
1.4 mM LiCl.
Analytical Techniques
Graphite furnace atomic absorption spectrometry with
Zeeman effect quantified lithium at 670.8 nm (Perkin Elmer
4100 ZL, Norwalk, CT, USA).
The samples were diluted 20-fold in 0.2% HNO3 before
injection.
Flame atomic absorption spectrometry (Perkin Elmer
AA Analyst 300, Perkin-Elmer Corporation) was used to
measure sodium and potassium concentrations in iontopho-
retic and donor samples. The ions were quantified at 589.1 nm
and 769.9 nm, respectively, after a 10-fold dilution of the
samples in 10% HNO3.
Ionic chromatography was used to quantify lithium, so-
dium, and potassium. The Dionex DX-600 system (Voisins le
Bretonneux, France) was equipped with a GP-50 pump and
an AS-50 thermal compartment (25°C). A 6 mM H2SO4 mo-
bile phase was pumped (1 ml/min) through a CS-16 cationic
column. Detection involved a ED-50 detector and an Atlas
suppressor (61 mA) .
Statistics
Data analysis, linear and nonlinear regressions were per-
formed with Graph Pad Prism V.4.0 (GraphPad Software Inc.
San Diego, CA, USA). All linear regressions shown in this
work were significant (p < 0.001). The data from each ionto-
phoresis cell was individually fitted to the corresponding re-
gression equation, and the “kinetic” values derived corre-
spond to the average and standard deviation (SD) of 6 cells.
Kruskal-Wallis and repeated measures ANOVA analysis
were performed with SigmaStat V.2.03 (SPSS Science Soft-
ware GmbH, Erkrath, Germany). The statistical significance
level was fixed at p < 0.05. (AUC)0→t was determined via the
trapezoidal method (Prism V.4.); (AUC)t→ was calculated
from the ratio of the last value measured to the elimination
constant rate (27).
RESULTS AND DISCUSSION
Fixed-Concentration Extraction Experiments
This first set of experiments verified the concentration
dependence of the lithium iontophoretic extraction flux over
the therapeutic range. Lithium was extracted at the cathode
as expected. Figure 1 shows that lithium flux stabilized after
approximately 2–3 h of iontophoresis. The delay results from
the fact that, when the current is started, the most readily
available charge carriers are the endogenous ions already
present inside the skin (18); only after this “reservoir” is de-
pleted can lithium assume its full role in transporting charge
across the barrier. Lithium transport became steady after a
few hours of iontophoresis, in a similar manner to that re-
ported for acetate (11), but more rapidly than valproate (∼5
h) (10) and phenytoin (>10 h) (11). The iontophoretic lithium
flux, when the “donor” concentration was 0.6 mM, reached
20.0 ± 1.0 nmol  h−1, a value nearly an order of magnitude
greater than that found for valproate (2.3 nmol  h−1) under
similar conditions (10). This illustrates the critical role of the
physicochemical properties of the analyte of interest in deter-
mining the feasibility of iontophoretic extraction. Lithium,
being smaller, more mobile and much less lipophilic than val-
proate, competes much better in carrying the charge across
the skin. Furthermore, electroosmosis assists lithium trans-
port while reducing that of the anionic valproate (19).
The relationship between lithium flux and subdermal
concentration was analyzed by linear regression [Eq. (3)], and
the results are in Table I:
JLi =   CLi (3)
Fig. 1. Reverse iontophoretic extraction fluxes of lithium as a func-
tion of time and subdermal lithium concentration. Each data point
represents the mean ± standard deviation (n  3).
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The values of the slope () progressively increased until the
third hour of extraction. Satisfactory correlation coefficients
were observed as early as 2 h after the initiation of iontopho-
resis (r2  0.85), with the best correlation obtained at 5 h
(r2  0.97). Overall, this first experiment demonstrated that
a linear relation between lithium extraction flux and the sub-
dermal concentration of the drug is established after a rela-
tively short sampling time.
Stepwise Concentration Change Experiments
The experiments began with an initial 2-h period of cur-
rent passage, during which the lithium subdermal concentra-
tion was maintained constant at either 0.95 mM or 1.7 mM
(Figs. 2a and 2b, respectively). During this time, the ionto-
phoretic fluxes increased and reached steady values faster
than observed before. This was probably due to the smaller
thickness of the skin membrane used (dermatomed vs. full-
thickness tissue) and the shorter sampling intervals used (30 min
vs. 1 h), which allowed the kinetics to be determined more
precisely.
The concentration of LiCl in the subdermal solution was
then changed in a stepwise fashion at 120 and 210 min: in
the first experiment, to 2.7 mM and 1.8 mM, respectively
Table I. Linear Regressions of the Iontophoretic Extraction Fluxes of
Lithium (JLi in Units of nmol/h) as a Function of the Drug’s Subdermal
Concentration (CLi in mM) After Different Times of Iontophoresis
(Data in Fig. 1), According to the Equation JLi   CLi + Intercept*
Time (h)  (l/h) r2
1 13 ± 6 0.43
2 31 ± 5 0.85
3 42 ± 6 0.89
4 44 ± 7 0.87
5 43 ± 3 0.97
* The absolute values of the intercepts were 9 nmol/h or less.
Fig. 2. Monitoring of lithium subdermal concentration changes: (a) first experiment, (b) second experiment. The
continuous lines indicate the stepwise changes in the subdermal lithium concentrations. The open squares are the
lithium iontophoretic fluxes. Each data point represents the mean ± standard deviation (n 6). Transport numbers
of lithium (tLi, open bars) potassium (tK, solid bars), and sodium (tNa, hatched bars) determined from the ionto-
phoretic fluxes in (c) the first experiment and (d) the second experiment. Linear regressions between the ratio of
extraction fluxes (RNa) and either the lithium subdermal concentration or the ratio of subdermal concentrations
(CLi/CNa) determined using the data from (e) the first experiment and (f) the second experiment.
Noninvasive Lithium Monitoring 1217
(Fig. 2a); in the second, to 0.6 and 1.1 mM (Fig. 2b). These
sudden changes, which are much more abrupt than any pos-
sible in an in vivo situation of course, were carried out to
test the responsiveness of reverse iontophoresis to such
variations.
Figure 2 shows that iontophoresis was quite efficient in
following the stepwise changes in the subdermal composition.
Lithium fluxes responded appropriately to the new conditions
established in each case and reached new steady values after
a relatively short delay. As the “physiological” buffer used
remained constant, increasing or decreasing the lithium con-
centration conferred, respectively, a better or worse chance
for the drug to compete to carry the charge across the skin
[i.e., to adopt a higher or smaller transport number (18)].
Taken together, the first two sets of experiments confirm
that reverse iontophoresis of a highly mobile drug, such as
lithium, can provide credible information about concentra-
tion changes occurring in the internal medium with a rela-
tively short time-lag.
Internal Standard Calibration
As discussed before, the Glucowatch Biographer re-
quires an initial calibration to be performed via a conven-
tional (“finger-stick”) blood measurement. Clearly, for thera-
peutic drug monitoring, an alternative, noninvasive calibra-
tion procedure is essential. We have, therefore, considered
the use of an internal standard calibration [Eq. (2)] (10). En-
dogenous electrolytes, such as sodium and potassium,
seemed, a priori, good candidates as internal standards for
lithium reverse iontophoresis. First, these are cations, ex-
tracted at the cathode and, like lithium, principally by elec-
tromigration. Second, their physiological concentrations are
normally quite constant, ranging from 135 to 143 mM for
sodium and between 3.3 and 4.6 mM for potassium (28).
To test this idea, potassium and sodium extraction fluxes
were also measured in the experiments discussed above. The
essential requirement for the internal standard is that its ex-
traction flux is independent of the target analyte concentra-
tion; in other words, that the transport number of the internal
standard is constant and is not affected by variations in the
analyte’s subdermal level. Figures 2c and 2d show the trans-
port numbers of the three cations calculated using the JLi data
in Figs. 2a and 2b and the corresponding measured values of
JNa and JK. It is apparent that the sodium and potassium
transport numbers were indeed constant within each experi-
ment, while that of lithium varied in proportion to the drug’s
subdermal concentration.
This finding is completely logical for sodium, which is
present subdermally at a much higher concentration than
lithium. When lithium transports a slightly greater or smaller
amount of charge, due to its subdermal level changing, so-
dium (as the major current carrier) is able to “take up the
slack” without a significant impact on its transport number
(18). On the other hand, for potassium, whose physiological
concentration is much closer to lithium’s therapeutic range,
one might have expected some compensation between the
transport numbers of the two cations. That this is not the case
may be explained by the fact that potassium is, in some re-
spects, a more “efficient” charge carrier than sodium; that is,
while sodium is 30 times more concentrated than potassium
in the subdermal solution, the ratio of their extraction fluxes
was only ∼20, meaning that potassium has the significantly
higher mobility of the two ions. It is not simply concentration,
therefore, which determines the absolute value of a transport
number.
The next step was to verify the validity of Eq. (2). The
regressions shown in Figs. 2e and 2f demonstrate the corre-
lations between the ratio of lithium to sodium extraction
fluxes (RNa) and either the lithium subdermal concentration,
or the ratio of the subdermal concentrations of the two ions.
When the corresponding regressions were performed for RK,
the correlations were satisfactory, though smaller (r2  0.89
and 0.83, respectively), presumably because of the slightly
higher variability observed in potassium fluxes as compared
to those of sodium. Nevertheless, overall, this component of
the study demonstrated unequivocally that the internal stan-
dard concept works in vitro and may constitute a viable ap-
proach to normalize lithium iontophoretic extraction for drug
monitoring purposes.
Concentration-Profile Kinetic Experiments
Further experiments examined whether transdermal ion-
tophoresis could be used to determine pharmacokinetic pa-
rameters noninvasively. This was evaluated by simulating two
classic plasma profiles in the subdermal compartment of the
iontophoretic cells. It should be noted that the goal of these
studies was to illustrate the versatility of reverse iontophore-
sis; there was no intention here to simulate “real” lithium
pharmacokinetics, which can be complex (4,29).
IV Bolus
The first kinetic profile considered was an IV bolus. The
one-compartment model was characterized by an average
volume of distribution of 4.54 ml (the mean subdermal com-
partment volume of diffusion cells) and a clearance of 1 ml/h
(the syringe pump rate of perfusion). The dose “injected” was
4.96 moles. The subdermal concentration profile should
therefore follow an exponential decay post-injection:
Ct = C0  e
−Ket (4)
where Ct and C0 are the lithium subdermal concentration at a
given time t and at t  0, respectively, and Ke is the elimi-
nation rate constant. Upon combination of i) Eqs. (3) and (4),
and ii) Eqs. (2) and (4), two testable hypotheses were defined
for this experiment, namely:
JLi =   C0  e
−Ket (5)
RI.S. = 
#  C0  e
−Ket (6)
where the significance of JLi, RI.S., , and 
# have been pre-
viously defined.
Throughout these experiments, sodium and potassium
extraction fluxes were constant averaging 9.4 mol/h (±4%)
and 0.55 mol/h (±11%), respectively. On the other hand, the
lithium fluxes, in general, tracked the changes in its subder-
mal concentrations. Figure 3 shows the lithium subdermal
concentration, the lithium extraction flux and the ratios of
extraction fluxes (JLi/JNa and JLi/JK) as a function of time
postinjection. In general, good agreement with the model is
observed. The subdermal concentration data allowed the ref-
erence values for the parameters characterizing the model to
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be determined (Table II). These experimental parameters
agreed well with the theoretical values cited above.
Figure 3 reveals that the values of JLi, RNa, and RK do
not conform to the expected profiles [Eqs. (5) and (6)] during
the first hour of extraction. In fact, the profiles are reminis-
cent of an oral administration, for example, with a very fast
absorption phase. After 1 h, however, the three profiles de-
creased in parallel with the subdermal Li concentration. It
appears therefore, that during the first hour, JLi, RNa, and RK
reflect two concurrent processes: i) the subdermal lithium
kinetics and ii) the establishment of steady iontophoresis ex-
traction fluxes across the skin. That is, until  and # become
constant, the JLi, RNa, and RK profiles report on both pro-
cesses. Once this is achieved, the extraction flux becomes
directly and proportionally dependent on the subdermal con-
centration, and the slopes of the lines in Fig. 3 are parallel.
Figure 4 presents the values of  and # as a function of
time. A repeated measures ANOVA demonstrates that  and
# become constant from the third sampling period (after
85 min of iontophoresis). Mean values for  (68.8 ± 1.7 l/h),
Na
# (7.3 ± 0.2 M−1), and K
# (114.1 ± 4.2 M−1) were deter-
mined by linear regression through the data obtained post
85 min of iontophoresis.
Linear regression of the semi-logarithmic data (after the
third sampling period) in Fig. 3 permitted the elimination rate
constant (Ke) to be determined from the iontophoretic ex-
traction data and compared to the reference value (Table II).
In general, Ke was slightly underestimated relative to that
calculated from the decay of the subdermal concentrations.
Nevertheless, overall, the agreement was really quite good.
One possible source of the differences observed is the time
required for the iontophoretic sampling. The data point at
85 min, for example, reflects a moving average, so to speak, of
the instantaneous values during the sampling period between
70 and 100 min. On the other hand, the subdermal CLi was
measured in a sample taken at exactly 85 min (i.e., the mid-
point of the iontophoretic extraction period). An analogy
may be drawn between measurements of urinary excretion
rates and plasma concentrations. Clearly, when comparing
kinetic parameters from the two types of measurement, the
degree of error (difference) becomes greater as the sampling
period increases. This fact has been recognized in the Gluco-
watch with which glycemia is now assessed every 10 min such
that very close tracking of glucose levels is possible. In the
end, analytical sensitivity is the determining factor—for
lithium, with the assay sensitivity and precision presently pos-
sible, 5–10 min sampling intervals are feasible.
The iontophoretic extraction data were next used to es-
timate additional pharmacokinetic parameters [including the
clearance (Cl) and volume of distribution (Vd)]. Equations
(5) and (6) indicate that C0 can be found provided that  and
#, respectively, are known. Knowing C0, it is then straight-
forward to assess Vd ( dose/C0) and Cl ( Ke  Vd). The
first step, therefore, was to identify the values of  and # to
be used. Figure 4 shows that these coefficients of proportion-
ality become reasonably constant after about 1.5 h of ionto-
Fig. 3. Simulated lithium bolus administration (top panel) and a
semi-logarithmic transformation of the data (bottom panel). The
solid squares are the subdermal lithium concentrations; the open
squares are the iontophoretic extraction fluxes of the drug (JLi). The
open circles and open triangles are, respectively, the extraction flux
ratios, RNa and RK. Each data point represents the mean ± standard
deviation (n 6). Solid lines of simple interpolation through the data
are shown in the top panel; the dashed lines in the bottom panel, on
the other hand, are linear regressions.
Table II. Pharmacokinetic Parameters Determined in the Bolus Experiment (Mean ± SD, n  6)
r2

Ke
(×10−3/min−1)
T1/2
(min)
C0*,†
(mM)
Vd*,†
(ml)
Cl*,†
(ml/h)
Cl*,‡
(ml/h)
CLi Subdermal 0.99 4.2 ± 0.3 168 ± 14 1.01 ± 0.06 4.9 ± 0.3 1.22 ± 0.05 1.21 ± 0.04
JLi 0.99 3.9 ± 0.2 180 ± 10 0.99 ± 0.06 5.0 ± 0.3 1.17 ± 0.02 1.21 ± 0.03
RK 0.96 3.6 ± 0.3§ 193 ± 15§ 0.97 ± 0.06 5.1 ± 0.3 1.10 ± 0.07§ 1.21 ± 0.09
RNa 1.00 3.8 ± 0.2 181 ± 9 0.98 ± 0.06 5.1 ± 0.3 1.17 ± 0.04 1.22 ± 0.06
* Values determined using , 
#, or ,Na
#, respectively.
† Calculated assuming a one-compartment model: Vd  dose/C0, Cl  KeVd.
‡ Model independent calculation using the corresponding area-under-the-curve.
§ Value significantly different from reference value obtained from the direct measurements of CLi (p <
0.05) (Kruskal-Wallis ANOVA on ranks).
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phoresis, and the mean values from this point on are the
logical choices for the determination of the pharmacokinetic
parameters of interest (Table II). The Vd and Cl determined
in this way are quite close to the reference values. Though this
type of calculation based on in vitro data is usefully illustra-
tive, it remains to be seen in vivo the extent to which  and/or
# vary within and between subjects; that is, will it be neces-
sary to determine  and/or # for every patient or will a popu-
lation average be sufficiently precise for all subjects? In the
former ease, of course, careful calibration with blood sam-
pling would be necessary for each person in order to define
the value of the constant(s) to be used.
Self-evidently, the internal standard calibration approach
leading to the deduction of # is envisaged as a means to
completely avoid calibration with blood sample. The con-
stancy of Na+ extraction in this work speaks to its consider-
able potential in this regard; on the other hand, potassium,
which was also evaluated, yielded more variable results. Cer-
tainly with Na+, then, the approach could be useful for a
therapeutic monitoring application during lithium therapy.
Care is necessary with respect to the kinetics, however, as a
finite time is required before  and # reach stable values
(Fig. 4). Whether this delay is partly an artefact, caused by the
experimental design in which Na+ and K+ extraction fluxes
were stabilized before Li was “injected” into the subdermal
solution, remains to be seen. In a recent study (10) examining
the idea of valproate monitoring by reverse iontophoresis,
and using glutamate as an internal standard, the value of #
was constant from the very first sampling period, even though
the extraction fluxes had not stabilized by this time. It is
important to note, in this case, that the two ions were intro-
duced simultaneously into the subdermal compartment. It fol-
lows that, for a patient receiving chronic lithium therapy, it is
reasonable to expect # to become constant more rapidly than
that observed in the in vitro work presented here.
Constant Rate Infusion
The second situation considered was a constant infusion
(5.6 moles/h) of lithium chloride into the subdermal com-
partment having Vd ∼4.54 ml. The clearance was 4 ml/h. The
drug concentration profile, in this case, is described by Eq. (7)
(27,30):
Ct = Css1 − e
−Ket =
K0
Ke  Vd
1 − e−Ket (7)
which predicts that CLi will increase exponentially to a steady-
state plateau, Css. Figure 5 shows that this plateau level
(∼1.3 mM) was attained after 3–3.5 h of perfusion. When the
subdermal concentration profile was fitted to equation 7
(r2  0.94, nonlinear regression), the following reference val-
ues were obtained; Ke 0.014 ± 0.001 min
−1; T1/2 50 ± 4 min;
Css  1.32 ± 0.03 mM; Vd  5.1 ± 0.3 ml; and Cl  4.2 ± 0.1
ml/h.
Figure 5 also demonstrates that the iontophoretic extrac-
tion of Li flux and the extraction flux ratios (RNa and RK) also
increased exponentially toward steady-state values, conform-
ing to the following equations, which result from the substi-
tution of Eqs. (3) and (2), respectively, into Eq. (7):
Jt = Jss  1 − e
−Ket =   Css  1 − e
−Ket (8)
Rt = Rss  1 − e
−Ket = #  Css  1 − e
−Ket (9)
The significance of JLi, RI.S., , and 
# are as before; Jss
and Rss represent the steady-state values of JLi and RI.S.,
respectively.
Interpretation and analysis of the iontophoretic extrac-
tion flux data were more complicated than the IV bolus case.
In the latter situation, the only “pharmacokinetic” process
taking place in the subdermal compartment is drug elimina-
tion. In contrast, in the infusion scenario, there is both “input”
and elimination; it should be recalled, furthermore, that the
time to steady-state under these circumstances is on the order
of four elimination half-lives. Again, because of these concur-
rent processes, the model described by Eqs. (8) and (9) fits
the results very well after about 1 h (when the two first
samples are omitted). The evolution of  and # with time is
shown in Fig. 6. It is first noted that the absolute values of
these parameters are very similar to those observed in the I.V.
bolus experiments (Fig. 4), supporting the contention that
these proportionality constants may show very small interin-
dividual differences. However, it takes longer (2.5–3 h) for
the values of  and # to stabilize in the infusion situation
(repeated measures ANOVA). At this point, it was deduced
Fig. 4. Proportionality constants  and # [defined in Eqs. (3) and (2),
respectively, and determined from the bolus experiment] vs. time.
Each data point represents the mean ± standard deviation (n  6).
Fig. 5. Iontophoretic monitoring of lithium during a simulated con-
stant infusion to steady-state. The subdermal lithium concentration
profile is represented by the solid squares, and the line through the
data is a fitted curve according to Eq. (7); the open squares are the
iontophoretic extraction fluxes of the drug (JLi) [data fitted to Eq.
(8)]. The open circles and open triangles are, respectively, the extrac-
tion flux ratios, RNa and RK [results fitted using Eq. (9)]. Each data
point represents the mean ± standard deviation (n  6).
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that   65 ± 14 l/h, K
#  135 ± 43 M−1, and Na
#  7.6
± 1.4 M−1. It is logical to suppose that the increased time for
stabilization is due to the fact that steady-state kinetics are
approached slowly in the experimental infusion model here
tested.
Thus, iontophoretic extraction fluxes become progres-
sively more reflective of the subdermal kinetics with increas-
ing time. When the iontophoretic data in Fig. 5 are fitted to
Eqs. (8) and (9), the values of Jss, and Rss are very close either
to the experimental results or to the theoretical value. Simi-
larly, the derived values for clearance were 4.1 ± 0.1 (from
JLi), 4.1 ± 0.2 (from RNa) and 4.1 ± 0.1 ml/hour (from RK)
which are in excellent agreement with the reference value of
4.2 ± 0.1 ml/h.
Estimation of Ke from the iontophoretic extraction data
was more challenging. This parameter was obviously under-
estimated when data from the earliest sampling times were
included (Fig. 7). When these initial results were omitted, the
fitting procedure improved (r2  0.8); for example, analysis of
data from 85 min onward resulted in values of Ke (in min
−1)
of 0.0095 ± 0.0003 (from JLi), 0.0091 ± 0.0009 (from RK), and
0.0091 ± 0.0005 (from RNa). The “reference” value, it is re-
called, was 0.014 min−1. Thereafter, if results only from the
latter half of the experiment are fitted (Fig. 7), the resulting
Ke increased somewhat but not significantly, and the good-
ness-of-fit decreased. It is not clear whether, in this experi-
ment, the iontophoretic fluxes could ever provide a better
estimation of Ke. Once steady-state is achieved, of course, the
sensitivity of the model to determine Ke is lost. It follows that
there is a temporal “window of opportunity” for the estima-
tion of Ke; long enough has to have elapsed so that the ex-
traction fluxes have caught up with the subdermal kinetics,
but not so long that steady-state is close to having been at-
tained. On the other hand, the results demonstrate an effec-
tive means with which to determine noninvasively, and quite
accurately, a drug’s clearance.
In conclusion, the results presented here demonstrates
that reverse iontophoretic monitoring of lithium is concentra-
tion-dependent, and that quantitative information about the
drug’s subdermal level can be obtained without a “blood”
measurement via the use of Na+ and/or K+ as an “internal
standard”. The iontophoretic extraction flux of Li, and the
ratio of this flux to that of either Na+ or K+, tracks pharma-
cokinetic changes in the drug’s subdermal concentration rap-
idly and faithfully, allowing the remarkably noninvasive de-
termination of certain pharmacokinetic parameters that are
presently available only via plasma or whole blood measure-
ments.
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